WHO panel assesses blood clot reports of AstraZeneca vaccine
WHO director general Tedros Adhanom Ghebreyesus said late Friday, As soon as WHO has gained a full understanding of these events, the findings and any changes to our current recommendations will be communicated immediately to the public WHO insists AstraZeneca vaccine safe as jab faces new setbacks
The World Health Organization on Friday said there was no reason to stop using AstraZeneca's Covid-19 jab after several countries suspended rollout ov Clot mystery thickens: Opinion divided over Astrazeneca vaccine roll-out
Thailand, Bulgaria delay jab launch; WHO, France, Germany support shot Top Cambodian leaders receive 1st shot of India-made Covid-19 vaccine
Cambodian leaders including President of National Assembly Heng Samrin, received the first shot of AstraZeneca's 'Made-in-India' CoviShield vaccines AstraZeneca Pharma gets DCGI nod for lung cancer treatment drug
AstraZeneca Pharma India on Wednesday said it has received marketing approval from the Drugs Controller General of India (DCGI)for its product for the treatment of non-small cell lung cancer. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Astrazeneca Pharma India Limited Receives Import And Market Permission In Form CT-20 (Subsequent New Drug Approval) From The Drugs Controller General Of India For Osimertinib 40Mg/80Mg Film Coated Tablets (Tagrissotm)
This is to inform that AstraZeneca Pharma India Limited has received Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the Drugs Controller General of India for Osimertinib 40mg/80mg film coated tablets (TagrissoTM). Osimertinib 40mg/80mg film coated tablets as monotherapy is now approved for additional indication for the adjuvant treatment after complete tumour resection in patients with non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets into a new disease area in India, subject to the receipt of related statutory approvals and licenses. COVID-19 vaccine: Govt signs fresh deal with Serum Institute for 20 million Covishield doses
The central government in January ordered 11 million doses of the Oxford-AstraZeneca COVID-19 vaccine from the Pune-based pharmaceutical Nepal receives 348,000 doses of made-in-India Covid-19 vaccines
The first COVAX shipment of 348,000 doses of AstraZeneca 'Covishield' vaccines arrived in Kathmandu, the embassy said in a tweet Sri Lanka receives Oxford-AstraZeneca vaccines under COVAX Facility
Sri Lanka on Sunday received the first batch of 264,000 doses of the Oxford-AstraZeneca vaccines provided under the World Health Organisation's COVAX facility AstraZeneca Pharma India Ltd - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of SEBI (LODR) Regulations, 2015, the Company is intimating the request received relating to Loss of share certificate and issue of duplicate share certificate as per attached details.